Reuters logo
5 months ago
BRIEF-TG Therapeutics' leukemia drug clears hurdle in late-stage study
March 6, 2017 / 12:21 PM / 5 months ago

BRIEF-TG Therapeutics' leukemia drug clears hurdle in late-stage study

March 6 (Reuters) - TG Therapeutics Inc:

* TG Therapeutics announces positive topline data from phase 3 genuine study of TG-1101 in combination with ibrutinib in patients with high risk chronic lymphocytic leukemia (CLL)

* TG Therapeutics - study met its primary endpoint, with tg-1101 (ublituximab) plus ibrutinib increasing overall response rate (ORR) by >70% over ibrutinib alone

* TG Therapeutics - combination was well tolerated with a safety profile consistent with phase 2 study of ublituximab plus ibrutinib

* TG Therapeutics Inc- full analysis of phase 3 genuine data along with detailed efficacy and safety results will be submitted for presentation at a medical meeting in first half of 2017

* TG Therapeutics - and company plans to meet with FDA as soon as possible thereafter to discuss filing of data for accelerated approval Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below